Scotland Greenlights More Rare Disease Treatments
Scotland’s health technology appraisal body has OKd Alynlam’s Onpattro, AstraZeneca's Imfinzi and Takeda’s Alunbrig for use on the Scottish National Health Service.
You may also be interested in...
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.